We are proud to announce initiation of a Phase 1 clinical trial of our antibody candidate SRF388, a first-in-class, fully human antibody targeting the immunosuppressive cytokine IL-27. Read more here: https://t.co/1cik5grcsT #biotech https://t.co/JNq8YzzVup